Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

FDA Panel Recommends Approval Of Chelsea Therapeutics' Northera

RELATED NEWS
Trade CHTP now with 

Chelsea Therapeutics International Ltd.(CHTP: Quote) announced that the Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee or CRDAC voted 7-4 with 1 abstention and 1 non-vote to recommend approval of Northera (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with primary autonomic failure (Parkinson's disease, multiple system atrophy and pure autonomic failure), dopamine beta hydroxylase deficiency and non-diabetic autonomic neuropathy.

A Prescription Drug User Fee Act (PDUFA) action date for the Northera NDA has been scheduled for March 28, 2012.

Click here to receive FREE breaking news email alerts for Chelsea Therapeutics International and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
First-time claims for U.S. unemployment benefits fell by much more than anticipated in the week ended September 13th, according to a report released by the Labor Department on Thursday, with claims pulling back near the fourteen-year low set in July. After ending the previous session mostly higher, stocks may see some further upside in early trading on Thursday. The major index futures are currently pointing to a higher open for the markets, with the Dow futures up by 44 points. Banks took up less-than-expected amount of funds at the European Central Bank's first targeted longer term refinancing operation, damping hopes of the success of the measure that was aimed to boost liquidity to help revive lending to small businesses and households.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.